FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jonas Schreyögg

Research Profile

Geographic Areas

Activities & Behaviors

Concepts & Ideas

Procedures

Organizations

European Union

Disorders

Co-author Network

Publications

TOP 3
Carl Rudolf Blankart; Taika Koch; Roland Linder; Jonas Schreyögg; Frank Verheyen; Tom Stargardt
Cost of illness and economic burden of chronic lymphocytic leukemia.
Oliver Tiemann; Jonas Schreyögg
Changes in hospital efficiency after privatization.
Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jonas Schreyögg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Carl Rudolf Blankart; Taika Koch; Roland Linder; Jonas Schreyögg; Frank Verheyen; Tom Stargardt
Cost of illness and economic burden of chronic lymphocytic leukemia.
Orphanet journal of rare diseases 2013;8(1):32.
2012: Oliver Tiemann; Jonas Schreyögg
Changes in hospital efficiency after privatization.
Health care management science 2012;15(4):310-26.
2012: Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
PharmacoEconomics 2012;30(9):763-77.
2012: Michael Bäumler; Jonas Schreyögg; Tom Stargardt; Reinhard Busse
Cost effectiveness of drug-eluting stents in acute myocardial infarction patients in Germany: results from administrative data using a propensity score-matching approach.
Applied health economics and health policy 2012;10(4):235-48.
2012: Jonas Schreyögg; Tom Stargardt
[Health economic evaluation based on administrative data from German health insurance].
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012;55(5):668-74.
2012: Carsten Schultz; Tom Stargardt; Jonas Schreyögg; Reinhard Busse
Focus on designing health care structures and services for rare diseases.
Health policy (Amsterdam, Netherlands) 2012;105(2-3):107-9.
2012: Tom Stargardt; Jonas Schreyögg
A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data.
Health policy (Amsterdam, Netherlands) 2012;105(2-3):110-8.
2011: K Roll; Tom Stargardt; Jonas Schreyögg
[Authorization and reimbursement of orphan drugs in an international comparison].
Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2011;73(8-9):504-14.
2011: Andreas K Buck; Ken Herrmann; Jonas Schreyögg
PET/CT for staging lung cancer: costly or cost-saving?
European journal of nuclear medicine and molecular imaging 2011;38(5):799-801.
2011: Helge Hollmeyer; Jonas Schreyögg; Ulrich Wahn; Doris Staab
Staff costs of hospital-based outpatient care of patients with cystic fibrosis.
Health economics review 2011;1(1):10.
2011: Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
PharmacoEconomics 2011;29(1):63-82.
2011: Jonas Schreyögg; Tom Stargardt; Oliver Tiemann
Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matching.
Health economics 2011;20(1):85-100.
2010: Jonas Schreyögg; Tom Stargardt
The trade-off between costs and outcomes: the case of acute myocardial infarction.
Health services research 2010;45(6 Pt 1):1585-601.
2010: Jonas Schreyögg; Julia Weller; Tom Stargardt; Ken Herrmann; Christina Bluemel; Tobias Dechow; Gerhard Glatting; Bernd J Krause; Felix Mottaghy; Sven N Reske; Andreas K Buck
Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(11):1668-75.
2010: Jonas Schreyögg; Markus M Grabka
Copayments for ambulatory care in Germany: a natural experiment using a difference-in-difference approach.
The European journal of health economics : HEPAC : health economics in prevention and care 2010;11(3):331-41.
2010: Andreas K Buck; Ken Herrmann; Tom Stargardt; Tobias Dechow; Bernd Joachim Krause; Jonas Schreyögg
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
Journal of nuclear medicine technology 2010;38(1):6-17.
2010: Andreas K Buck; Ken Herrmann; Tom Stargardt; Tobias Dechow; Bernd Joachim Krause; Jonas Schreyögg
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(3):401-12.
2009: Jonas Schreyögg; Michael Bäumler; Reinhard Busse
Balancing adoption and affordability of medical devices in Europe.
Health policy (Amsterdam, Netherlands) 2009;92(2-3):218-24.
2009: Franz Porzsolt; Jonas Schreyögg
[Scientific evidence and the cost of innovations in the health-care system].
Medizinische Klinik (Munich, Germany : 1983) 2009;104(8):622-30.
2008: Marc Diensthuber; Marc Potinius; Thomas Rodt; Alexandru C Stan; Hans-J Welkoborsky; Madjid Samii; Jonas Schreyögg; Thomas Lenarz; Timo Stöver
Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.
Journal of neuro-oncology 2008;89(2):131-9.
2008: Jonas Schreyögg; Constantin von Reitzenstein
Strategic groups and performance differences among academic medical centers.
Health care management review 2008;33(3):225-33.
2008: R Blankart; Jonas Schreyögg; Reinhard Busse
Performance of reimbursement schemes in valuation of technologies: the example of magnetic resonance imaging.
Technology and health care : official journal of the European Society for Engineering and Medicine 2008;16(3):171-82.
2008: Reinhard Busse; Jonas Schreyögg; Peter C Smith
Variability in healthcare treatment costs amongst nine EU countries - results from the HealthBASKET project.
Health economics 2008;17(1 Suppl):S1-8.
2008: Jonas Schreyögg
A micro-costing approach to estimating hospital costs for appendectomy in a cross-European context.
Health economics 2008;17(1 Suppl):S59-69.
2008: Jonas Schreyögg; Oliver Tiemann; Tom Stargardt; Reinhard Busse
Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories.
Health economics 2008;17(1 Suppl):S95-103.
2007: Friederike Burgdorf; Jonas Schreyögg; Wolfram Keller; Jörn von Wietersheim; Hans-Christian Deter
[Predictors of health-care utilization of patients with Crohn's disease: results of a prospective randomized multicenter trial].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(11):881-7.
2007: Tom Stargardt; Jonas Schreyögg; Reinhard Busse
Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany.
Health policy (Amsterdam, Netherlands) 2007;84(1):30-8.
2006: Jonas Schreyögg; Oliver Tiemann; Reinhard Busse
Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system?
Health care management science 2006;9(3):269-79.
2006: Jonas Schreyögg; Tom Stargardt; Oliver Tiemann; Reinhard Busse
Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries.
Health care management science 2006;9(3):215-23.
2006: Reinhard Busse; Jonas Schreyögg; Peter C Smith
Hospital case payment systems in Europe.
Health care management science 2006;9(3):211-3.
2006: Markus M Grabka; Jonas Schreyögg; Reinhard Busse
[The impact of co-payments on patient behavior: evidence from a natural experiment].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(6):476-83.
2006: Tom Stargardt; Jonas Schreyögg
Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Applied health economics and health policy 2006;5(4):235-47.
2006: Jonas Schreyögg; Helge Hollmeyer; Miriam Bluemel; Doris Staab; Reinhard Busse
Hospitalisation costs of cystic fibrosis.
PharmacoEconomics 2006;24(10):999-1009.
2006: H Auerbach; Jonas Schreyögg; Reinhard Busse
Cost-effectiveness analysis of telemedical devices for pre-clinical traffic accident emergency rescue in Germany.
Technology and health care : official journal of the European Society for Engineering and Medicine 2006;14(3):189-97.
2005: Jonas Schreyögg; Tom Stargardt; Marcial Velasco-Garrido; Reinhard Busse
Defining the "Health Benefit Basket" in nine European countries. Evidence from the European Union Health BASKET Project.
The European journal of health economics : HEPAC : health economics in prevention and care 2005;Suppl():2-10.
2005: Reinhard Busse; Tom Stargardt; Jonas Schreyögg
Determining the "Health Benefit Basket" of the Statutory Health Insurance scheme in Germany: methodologies and criteria.
The European journal of health economics : HEPAC : health economics in prevention and care 2005;Suppl():30-6.
2005: Reinhard Busse; Jonas Schreyögg; Klaus-Dirk Henke
Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?
The International journal of health planning and management 2005;20(4):329-49.
2005: Tom Stargardt; Jonas Schreyögg; Reinhard Busse
[Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2005;67(7):468-77.
2004: Jonas Schreyögg
[Justice in health care systems from an economic perspective].
Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2004;66(1):7-14.